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Objectives: HIV-associated lipodystrophy is a common comorbidity in HIV-infected
patients, having a profound impact on every aspect of patients’ lives, particularly when
involving the face. Hence, it is of the utmost importance to evaluate the result of any
potential therapies that may help solve HIV-associated facial lipodystrophy. The aim of
this article was to evaluate the outcome of patients undergoing facial lipodystrophy cor-
rection surgery within our institution. Methods: A retrospective analysis of the clinical
charts and iconographic information of patients regarding demographics, morphologic
changes, surgical option, postoperative complications, results, and patient satisfaction
assessed by a 1- to 10-point scale and by the Assessment of Body Change and Distress
questionnaire. Results: Twenty-three patients were operated on from March 2011 to
April 2015. Seventy-five percent of cases were treated with fat graft injection, whereas
dermis-fat grafts were applied in 25% of patients. The former had their fat harvested
more commonly from the abdomen, whereas in the latter case, the graft was harvested
mostly from the inner aspect of arms. The mean volume of fat injected on each side of
the face was 28.5 ± 22.7 mL. On a scale from 1 to 10, mean patient satisfaction was 7.7
± 2.8. The Assessment of Body Change and Distress questionnaire revealed statistically
significant improvements. Complications occurred in 25% of cases, the most frequent
being significant reabsorption. No major complications occurred. Conclusions: Treat-
ment of HIV-associated facial lipodystrophy with autologous fat or dermis-fat compound




First described in 1998,1 HIV-associated lipodystrophy is a common comorbidity
characterized by morphologic changes (central fat accumulation and peripheral fat atrophy)
and metabolic changes (hyperlipidemia and insulin resistance).2
According to Cabrero et al,3 based on a series of 965 HIV-infected patients, the
prevalence of perceived body physical changes in HIV-infected patients treated with highly
active antiretroviral therapy is around 55%, with the majority complaining about lipoatrophy
(47%). Other authors, with smaller series, have reported rates of lipoatrophy ranging from
13% to 63%.4
The most common site for lipoatrophy is the face,5 a place not hidden by clothes. This
change makes patients look ill or older, although their immune status may be excellent. This
may lead to poorer adherence and even failure of antiretroviral therapy,6 as well as erosion
of self-image and self-esteem, problems in social and sexual relations, forced HIV/AIDS
disclosure, and demoralization and depression.7
Although objective evaluation of different treatments of facial lipodystrophy is there-
fore very important, few studies have been conducted concerning this subject. The purpose
of this article was to evaluate the outcome of patients undergoing facial lipodystrophy
correction surgery within our institution.
METHODS
A retrospective analysis of the clinical charts and iconographic information of patients re-
garding demographics, morphologic changes, surgical option, postoperative complications,
results, and patient satisfaction was carried out on all HIV-infected patients operated on
within our institution from March 2011 to April 2015. Patient permission for taking and
including photographs in the clinical charts and for publishing purposes was obtained.
Surgical technique
Patients were evaluated for the availability of fat tissue. Those with insufficient fat tissue
underwent a dermis-fat compound graft transfer, and the remaining a fat graft transfer.
Patients were operated on under general anesthesia in an outpatient basis, except for the
first 2 patients. They received preoperatively prophylactic antibiotic therapy with amoxi-
cillin/clavulanic acid and metronidazole, which was continued for 5 days postoperatively.
When fat graft transfer was chosen, the Coleman technique was used, and both the
donor and receptor sites were infiltrated with Klein’s solution. Beside the Bichat fat pad,
we focused on grafting not only the superficial nasolabial, middle, and medial cheek fat but
also the deeper planes—the deep medial cheek fat compartment and Ristow’s space. We
deliberately aimed at slightly overcorrecting the fat defect.
When dermis-fat grafts were chosen, an ellipsoid-shaped dermis-fat graft measuring
about 4 × 10 cm with 1-cm thickness was harvested from the inner aspect of arms, lower
abdomen, medial aspect of thighs, and groin region and the primary defect primarily closed.
The graft was inserted through two 5-mm-long incisions placed according to the Langer
lines in or parallel to the nasolabial fold, with the dermis facing the deep aspect of the
wound. The graft was secured with subcuticular interrupted 4/0 Monocryl sutures.
Patients wore a facial bandage and were instructed to avoid facial gesticulation and to
keep the head elevated for 1 week.
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Patient satisfaction
Patient satisfaction was regularly assessed on a scale of 1 to 10 and by the Assessment of
Body Change and Distress (ABCD) original questionnaire, both after the sixth month of
follow-up.
Statistical analysis
The data were inserted in an Excel database. Qualitative variables were expressed as per-
centages. Quantitative variables were expressed as means ± standard deviation. The SPSS
21.0 software was used for descriptive and inferential statistical analyses. The Kolmogorov-
Smirnov test was used to assess whether variables were normally distributed. Analysis of
variance and the Student t test were used to compare averages in normally distributed
data. The Kruskal-Wallis and Mann-Whitney U tests were used to compare means in non-
normally distributed data. Proportions were analyzed with the χ2 test or the Fisher exact
test. Dichotomous variables were compared with the binomial test. A 2-tailed P value of
less than .05 was considered to be statistically significant.
RESULTS
Patient characteristics, technical considerations, complications, and results concerning sat-
isfaction with the procedure are presented in Table 1 and Figures 1 and 2.
Twenty-three patients ranging in age from 35 to 67 years (50.2 ± 8.1 years) were
operated on within our institution from March 2011 to April 2015. Minimum follow-up
time was 6 months (average time of follow-up was 28.5 ± 12.7 months). Surgery was most
commonly performed on males than on females (79.2% vs 20.8% of cases; P = .007).
Seventy-five percent of cases were treated with fat graft injection, whereas dermis-fat
compound grafts were applied in 25% of patients (P = .023). In patients undergoing fat
grafting, the donor site was the abdomen, dorsal cervical fat pad, abdomen and thighs,
and adipomastia in 77.8%, 11.1%, 5.6%, and 5.6% of the cases, respectively. In patients
undergoing dermis-fat compound graft, the graft was harvested from the inner aspect of
arms, lower abdomen, inner aspect of thighs, and groin region. The first corresponded to
50% of cases of compound graft harvesting, whereas the remaining regions were used in
16.7% of cases each.
The mean volume of fat injected on each side of the face was 28.5 ± 22.7 mL, with a
range from 5 to 100 mL. There was no statistically significant difference between the mean
volume injected in each gender.
Three-fourths of patients (n = 17) had no complication of the volume enhancement
procedure. Complications occurred in 25% of cases (n = 6), the most frequent being
significant reabsorption (n = 4; 16.7%), followed by hypertrophy and hematoma (n = 1;
4.2% each). In the patients in whom significant reabsorption was as issue, progressive loss
of volume up to the sixth month postoperatively was observed. One patient with significant
reabsorption was reoperated on, whereas the remaining cases with significant reabsorption




















1 M 45 Fat graft Dorsocervical
fat pad
100 x 8 2 5 27 20
2 M 52 Dermis-fat
graft
Abdomen . . . Hematoma 10 NA
3 M 44 Dermis-fat
graft
Arms . . . Significant
reabsorption
1 NA
4 M 51 Fat graft Dorsocervical
fat pad
NA x NA NA
5 M 66 Dermis-fat
graft
Thighs . . . x 5 4 4 20 20
6 M 50 Fat graft Adipomastia NA Hypertrophy 8 NA
7 M 45 Dermis-fat
graft
Arms . . . x 8 NA
8 M 52 Fat graft Abdomen 25 x 10 NA
9 M 61 Fat graft Abdomen 45 Significant
reabsorption
10† 3 5 65 32
62 Fat graft Abdomen 25 x
10 M 67 Fat graft Abdomen 20 x 8 1 4 55 22
11 M 50 Fat graft Abdomen 30 x 9 1 5 55 22
12 F 48 Fat graft Abdomen 12 x 10 NA
13 F 56 Fat graft Abdomen 30 x 9 NA
14 M 40 Fat graft Abdomen +
thighs
25 x 10 NA
15 M 47 Fat graft Abdomen 12.5 x 9 2 5 57 28
16 M 37 Dermis-fat
graft
Arms . . . x 8 2 4 50 26
17 M 48 Fat graft Abdomen NA x NA NA
18 F 51 Fat graft Abdomen NA Significant
reabsorption
4 3 5 68 36
19 M 57 Fat graft Abdomen 20 x 10 1 5 20 60
20 F 36 Fat graft Abdomen 20 x 8 NA
21 M 47 Fat graft Abdomen 5 Significant
reabsorption
1 NA
22 M 47 Dermis-fat
graft
Groin . . . x 10 NA























































∗Numeric variables are expressed as mean values ± standard deviation. ABCD indicates Assessment of Body Change and
Distress; NA, not available.
†After the second procedure.
Early on in our experience, we faced a case of hypertrophy in a patient who had his fat
harvested from adipomastia. From then on, based on this experience and other reports,8 we
stopped harvesting fat from overly hypertrophic regions. Apart from these adverse cosmetic
outcomes and 1 hematoma case, we had no major complications or iatrogeny.
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Figure 1. Pre- and postoperatively at 1 year: front.
Figure 2. Pre- and postoperatively at 1 year: side.
No differences in complication rates were found between fat graft and dermis-fat
compound graft, nor between genders.
Concerning patient satisfaction, on a scale from 1 to 10, the average final result was
7.7 ± 2.8. No statistically significant differences were found between genders, nor between
fat graft versus dermis-fat compound graft. Although mean patient satisfaction was only
slightly different, results with dermis-fat compound grafts were, in our opinion, inferior to
those of fat grafts.
The ABCD questionnaire revealed a mean increase in the score for question 7 from
2.1 ± 1.0 to 4.7 ± 0.5 (P < .001) and a mean decrease in the score for question 8 from




Facial lipoatrophy is arguably the most stigmatizing condition of HIV lipodystrophy. How-
ever, scarce data are available concerning the efficacy of different treatments for this
condition. In our country, for example, no study has ever been published on this subject, as
far as we could determine.
As Guaraldi et al9 stated, the greatest pharmacological culprits behind lipoatrophy
are undoubtedly thymidine analogues, in particular stavudine and zidovudine, used for
protracted periods of time, which, via mitochondrial toxicity, promote adipose tissue loss.10
However, other risk factors are strongly associated with lipoatrophy, such as advancing age,
any use of stavudine, use of indinavir for longer than 2 years, body mass index loss, and
varying degrees of duration and severity of HIV disease.11 New drug regimens have a lesser
tendency to cause facial lipoatrophy.12,13 However, once settled, this condition has to be
addressed surgically. The most common options include autologous fat transfer, dermis-fat
compound graft transfer, and synthetic fillers.
Yang et al,14 using computed tomographic scans, found differences in subcutaneous
cheek and Bichat fat pad fat volume up to 15 and 4 mL, respectively, per side in moderate to
severe lipoatrophy versus controls. Although previously unclear, it is now well documented
that the Bichat fat pad is significantly depleted, although the extent of depletion (with an
average volume of 60% compared with controls) appears less than that of the superficial
fat depletion (with an average volume of 45% compared with controls).14
Synthetic fillers can provide a good cosmetic result. However, biodegradable fillers
may require multiple treatment sessions to achieve a satisfactory result and they are not long-
lasting. Hyaluronic acid gel lasts for a maximum of 8 months. Poly-L-lactic acid (PLA)
and calcium hydroxyapatite (CaHA) are also degraded, but the extent of the depletion
may be less because the fibrosis they induce is permanent. Nonbiodegradable fillers may
achieve a final and permanent result in only 1 session. However, they tend to migrate. In
our series, we first removed Bio-Alcamid (polyalkylimide) gel in 3 patients because of
inferior migration. Granulomas are not uncommon, especially with silicone gel and with
gels containing microparticles such as polymethylmethacrylate, PLA, and CaHA. Another
problem with almost all fillers is that they are expensive.5,9
Since the work of Coleman,15 it is known that lipostructure represents a safe and
long-lasting method of recontouring the face with autologous tissue. Notwithstanding, its
applicability to the HIV-associated facial lipodystrophy has been a subject of debate.
On the basis of the published data of Rohrich et al16,17 and Gierloff et al,18 who
presented the fat compartments of the face and their aging changes, we focused on filling
not only the nasolabial, middle, and medial cheek fat but also the deeper planes—the deep
medial cheek fat compartment and Ristow’s space.
With patient satisfaction as the main goal, we not only assessed it with a 1- to 10-point
scale but also applied the ABCD questionnaire. This questionnaire was developed by the
Adult AIDS Clinical Trials Group of the US National Institute of Allergy and Infectious
Diseases and has been specifically designed for the HIV-infected population.19,20 The first
question, the so-called question 7 (ABCD7), is about body image satisfaction and the score
ranges from 1 to 5, with 5 being “very satisfied”. The remaining 20 questions are collectively
called question 8 (ABCD8). This set of questions explores body change interference with
habits, attitudes, and social life, and the total score ranges from 20 to 100. The higher
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the score, the higher the interference. Although we found it a good tool for whole-body
evaluation, it is not face-oriented, which can cause some bias.
On a scale from 1 to 10, the average final result was 7.7 ± 2.8. No statistically significant
differences were found between genders, nor between fat graft versus dermis-fat compound
graft. Comparing the results of the ABCD questionnaire pre- and postoperatively regarding
questions 7 and 8, there was an increase in mean values in question 7 and a decrease in
mean values in question 8, which were statistically significant (P < .001). These changes
suggest that there was a clear beneficial effect of the treatment used in this series.
As stated earlier, although mean patient satisfaction was only slightly different, results
with dermis-fat compound grafts were, in our opinion, inferior to those of fat grafts. Worse
preoperative condition, difficulty in overcorrecting, and a tendency toward reabsorption of
the dermis-fat compound graft beyond the sixth month may have contributed to a perceived
worse aesthetic result in the former group of patients.
In the present series, mean fat volume injected was 28.5 ± 22.7 mL per side of the
face. Homologous values in the literature are highly variable and frequently include
the volume injected not only in the cheek, as we did in the present article, but also in
the temporal and preauricular area. Specifically addressing mean cheek volume, they range
from 7.8 to 10.5 mL of fat.21,22 This discrepancy may be explained by a greater severity
of lipoatrophy in the patients referred to our center. However, further studies, preferably
performed prospectively, are warranted.
There were 3 cases of significant reabsorption. As described in the “Results” section,
we noticed a general tendency of gradual reabsorption up to the sixth month postoperatively.
Other authors have reported reabsorption up to 1 year, with the majority occurring 6 to
9 months after treatment, whereas others have reported any trend toward reabsorption for
a minimum of 1 year.23,24 Interpretation of results may be confounded by the perpetuation
of the same drug, host, and disease risk factors for lipodystrophy that keep affecting the
native and probably the grafted fat.
A very significant advantage of autologous reconstruction of the face in patients with
HIV-associated facial lipodystrophy is probably a better compliance with antiretroviral
therapy.25 By having this opportunity at hand, patients do not have to choose between
optimal medical therapy and maintenance of their original look.
Overall, surgical treatment of HIV-associated facial lipodystrophy with autologous fat
or dermis-fat compound graft was a safe procedure with long-lasting results and unques-
tionable aesthetic and social benefits in the present series.
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